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L E T T E R  T O  T H E  E D I T O R
Gastrointestinal bleeding in a newborn infant with congenital 
factor X deficiency and COVID-19—A common clinical feature 
between a rare disorder and a new, common infection
Dear editor,
Congenital factor X (FX) deficiency is an extremely rare, bleeding 
disorder with an estimated incidence of one per 1 million. Patients 
with severe FX deficiency (FX:C < 1%) demonstrate a wide spectrum 
of serious clinical presentations, including hemarthrosis, hematoma, 
gastrointestinal (GI) bleeding, intracranial hemorrhage (ICH), and 
umbilical cord bleeding.1 In fact, severe FX deficiency, with a high 
rate of life-threatening bleeding, is the second-most severe, rare co-
agulation factor deficiency (RCFD) after FXIII deficiency.1,2 Although 
homozygotes are at risk of severe bleeding, heterozygotes usually 
are asymptomatic, but postsurgical bleeding or bleeding after child-
birth may occur.1,2 Other risk factors can increase the risk of bleeding 
in FX deficiency, and coronavirus disease 2019 (COVID-19), a new 
medical challenge, could affect the patient's bleeding or thrombotic 
tendency.3 COVID-19, which is caused by severe acute respiratory 
syndrome coronavirus 2 (SARS-CoV-2) presents an enormous chal-
lenge for everyone, especially for those with underlying risk factors 
such as cardiovascular disease, diabetes, obesity, and renal failure. 
Age and male sex are other risk factors.4 Limited data are available 
regarding the effect of COVID-19 on patients with congenital bleed-
ing disorders (CBDs), particularly RCFDs.5 It has been shown that 
hypercoagulability-related adverse consequences are less common 
among patients with CBDs, at least in those with moderate-to-se-
vere deficiency, but further studies, including our ongoing work on a 
large number of patients, are required.5 Although there are several 
reports of newborns among infected pregnant mothers, this is the 
first report of such a case in an RCFD. This case report may help 
medical professionals to better manage similar cases. A 19-year-old 
pregnant woman was infected with SARS-CoV-2 early in the 9th 
month of pregnancy. Reverse transcriptase-polymerase chain reac-
tion (RT-PCR) confirmed the infection. The patient had been in close 
contact with family members with confirmed COVID-19. The patient 
had cough and fever. Due to the mild presentation, she was given 
Azithromycin and advised to isolate herself at home. The symptoms 
resolved within 14 days. At end of her 9th month, three days prior 
to the planned cesarean section, she was rechecked for SARS-CoV-2 
infection; her RT-PCR was negative. She successfully underwent ce-
sarean section without complications and delivered a healthy full-
term baby. Therefore, mother and newborn discharged the following 
morning. In the evening, the baby experienced bloody vomiting and 
was hospitalized for further assessment, which showed GI bleeding. 
At admission, laboratory tests showed a positive C-reactive pro-
tein (CRP) (qualitative), a low hemoglobin level, and prolonged 
prothrombin time (PT), and activated partial thromboplastin time 
(APTT) (Table 1). He was hospitalized in the neonate intensive care 
unit (NICU) for 10 days. Due to the risk of SARS-CoV-2 infection, 
on the third day after admission he was tested by RT-PCR, which 
was positive. The neonate received 30 mL frozen plasma (FFP) six 
times over 10 days, which resolved the GI bleeding. Tranexamic acid 
(TXA) was administered at a dose of 10 mg/kg every 8 hours. Due 
to lack of COVID-19 symptoms, he did not receive any special treat-
ment for the disorder. After 10-day hospitalization in the NICU, the 
neonate was sent to an isolation room for 5 days, during which his 
condition stabilized, after which he was discharged in stable condi-
tion. He has had no complications during the past two months after 
discharge. Since the child's father and two other first-degree family 
members have severe FX deficiency, and the parents of the baby are 
closely related, the mother and the baby were checked for FX defi-
ciency. Routine coagulation tests, and FX:C assay performed by STA 
Compact automatic coagulometer (Stago, Paris, France), revealed a 
severe deficiency in the baby, and a mild deficiency, compatible with 
heterozygote FX deficiency, in the mother (Table 1).
COVID-19 is an emerging medical challenge that can present 
more difficulties for those with special conditions, such as pregnant 
women and newborns. Due to alterations in cellular immunity, preg-
nant women are more prone to infection by intracellular pathogens 
like viruses.6 The fetus is also highly susceptible to infection due to 
immaturity of the immune system.7 Furthermore, the mother's (het-
erozygote) congenital coagulopathy and that of her newborn (homo-
zygote) were additional potential risk factors, because a disrupted 
coagulation system is a prominent feature of SARS-CoV-2 infection.8 
To date, FX deficiency in a newborn has not been cited anywhere as a 
special condition requiring close attention in the case of SARS-CoV-2 
infection. According to the few reports to date, SARS-CoV-2 infec-
tion is a risk factor for severe maternal morbidity. It is worth noting 
that most of those mothers were discharged without complications.9 
From a clinical aspect, fever was the most common symptom (68%) at 
the time of admission.9 This was also observed in the affected woman 
of this study. SARS-CoV-2 infection can even affect the type of de-
livery. A systematic review of these women showed that about 92% 
of deliveries were by cesarean section, less than 10% being the usual 
vaginal delivery (7 of 85). Fetal distress was mentioned as the most 
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common indication for cesarean section. Our patient underwent a 
planned cesarean section, due to her previous history. The delivery 
itself was uneventful, and a healthy baby was delivered, while among 
other reported cases, a number of complications have been noted.9 
As with most other reports, the infant did not have any symptoms 
at the time of delivery and was discharged the day after birth.9 In 
a case series of 10 patients, various first clinical presentations were 
observed, including shortness of breath (n = 6), fever (n = 2), vomit-
ing (n = 1), and rapid heart rate (n = 1).10 In the case at hand, bloody 
vomiting was the first clinical presentation. In the same case series, 
one died due to refractory shock, multiple organ failure (MOF), and 
disseminated intravascular coagulation (DIC). Another patient with 
severe presentation was managed by intravenous infusions of gamma 
globulin, platelets, and plasma, which was suggestive of the effective-
ness of gamma globulin in severe cases. The author recommended 
early use of intravenous gamma globulin for passive immunization.10 
GI bleeding in our case was successfully managed by administration 
of FFP and TXA. In addition to thrombotic complication, bleeding 
is not infrequent in patients affected by COVID-19, with GI bleed-
ing seemingly the most common hemorrhagic manifestation among 
adults. GI bleeding, with a frequency of 40%, was observed among 
neonates from affected mothers.3 On the other hand, GI bleeding is 
also a relatively common presentation among severely FX deficient 
patients.1,2 In fact, GI bleeding can occur in children with severe FX 
deficiency within the first months of life. It seems that such patients 
are prone to experience severe bleeding, such as ICH, later in life, in 
the absence of an appropriate therapeutic strategy, most likely pre-
ventative regular secondary prophylaxis.1,2 In one study of 102 pa-
tients with congenital FX deficiency, GI bleeding has been reported 
in 12% of symptomatic cases.1 In this case, with GI bleeding being 
a common presentation of SARS-CoV-2 infection and congenital FX 
deficiency, it cannot definitively be attributed to one or the other. 
Close monitoring of such cases is necessary to decrease related ad-
verse consequences. Although it seems that COVID-19 is less severe 
in adults with CBDs, it is a less-known issue among children and new-
borns with CBDs. Further reports and studies could provide clarity. 
Due to their severe bleeding tendency, close monitoring of patients 
with severe congenital FX deficiency is mandatory, even without 
potential SARS-CoV-2 infection. And close monitoring of neonates 
with infected mothers is mandatory to prevent severe consequences. 
Patients with concomitant infection with SARS-CoV-2 require even 
more rigorous preventative and supportive care.
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TA B L E  1   Laboratory characteristics of mother and baby with factor X deficiency and COVID-19
Test
Proband (2nd day 
after birth)
Proband (7th day 
after birth)
Proband (2 months after 
hospital discharge)
Mother (about 3 1/2 months after 
SARS-CoV-2 infection)
WBC × 109/L 14.2 (8-24)a ,b  9.43 (5-21) 10.79 (6-18) 8.7 (3.6-10.6)
RBC × 109/L 2.5 (4.36-5.96) 2.78 (4.2-5.8) 3.50 (3.4-5) 4.41 (3.8-5.2)
Hb (g/dL) 8.2 (16.4-20.8) 9.2 (15.2-20.4) 10.2 (10.6-16.4) 13.6 (12-15)
HCT (%) 24.6 (48-68) 27 (50-64) 29.2 (32-50) 41.4 (35-49)
Lymphocyte × 109/L 6.4 (1.3-11) 4.3 (1.2-11.3) 8.21 (2.5-13) 2.22 (1-3.2)
Neutrophil × 109/L 4.9 (2.6-17) 2.9 (1.5-12.6) 1.85 (1.2-8.1) 5.75 (1.7-7.5)
Platelet × 109/L 370 (150-450) 331 (150-450) 334 (150-450) 276 (150-450)
PT (sec) >60
(PTC: 12.6)
90
(PTC: 12.6)
>60
(PTC: 10)
13
(PTC: 10)
APTT (sec) >120
(APTTC: 31)
100
(APTTC: 30)
>120
(APTTC: 32)
37
(APTTC: 32)
CRP (Quantitative) Trace Negative NC NC
FX:C level NC NC <1% (50%-150%) 40% (50%-150%)
Abbreviations: APTT, activated partial thromboplastin time; APTTC, APTT control; CRP, C-reactive protein; Hb, hemoglobin; HCT, hematocrit; NC, 
Not checked; PT, prothrombin time; PTC, PT control; RBC, red blood cell; WBC, white blood cell.
aHematological test normal ranges are extracted from Rodak's Hematology: Clinical Principles and Applications, 5th Ed (2016). 
bNormal values are placed in parentheses. 
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